Drug induced QT prolongation: Lessons from congenital and acquired long QT syndromes

Current Drug Targets - Cardiovascular and Haematological Disorders

Volumn 3, Issue 4, 2003, Pages 327-335

  Walker, Bruce D ^a   Krahn, Andrew D ^a,b   Klein, George J ^a   Skanes, Allan C ^a   Yee, Raymond ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BEPRIDIL; BRETYLIUM; CHLOROQUINE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DIGOXIN; DISOPYRAMIDE; DOFETILIDE; DOXORUBICIN; ERYTHROMYCIN; FLUCONAZOLE; HALOFANTRINE; IBUTILIDE; ION CHANNEL; ITRACONAZOLE; KETOCONAZOLE; LIDOFLAZINE; PENTAMIDINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; PRENYLAMINE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SOTALOL; SPIRAMYCIN; UNINDEXED DRUG; WARFARIN;

ADULT; CASE REPORT; CHANNEL GATING; CHROMOSOME 11; CHROMOSOME 21; CHROMOSOME 3; CHROMOSOME 4; CHROMOSOME 7; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FEMALE; GENE LOCUS; GENE MUTATION; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART REPOLARIZATION; HEREDITY; HOSPITAL ADMISSION; HUMAN; LONG QT SYNDROME; PATHOGENESIS; PATIENT CARE; POTASSIUM CURRENT; REVIEW; SYNCOPE; TORSADE DES POINTES; TREATMENT FAILURE; URINARY TRACT INFECTION;

ANTI-ARRHYTHMIA AGENTS; FEMALE; HUMANS; LONG QT SYNDROME; MIDDLE AGED; POTASSIUM CHANNELS; TORSADES DE POINTES;

EID: 0347478142     PISSN: 15680061     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568006033481393     Document Type: Review

References (49)

1. Moss, A. J., Schwartz, P. J., Crampton, R. S., Locati, E. and Carleen, E. The long QT syndrome: a prospective international study. Circulation, 1985, 71(1), 17-21.
2. Vincent, G. M. The molecular genetics of the long QT syndrome: genes causing fainting and sudden death. Annu. Rev. Med., 1998, 49, 263-274.
3. Priori, S.G., Barhanin, J., Hauer, R.N, Haverkamp, W., Jongsma, H.J., Kleber, A.G., McKenna, W.J, Roden, D.M., Rudy, Y., Schwartz, K., Schwartz, P.J., Towbin,J.A. and Wilde, A.M. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. Circulation, 1999, 99, 518-528.
4. Priori, S.G., Barhanin, J., Hauer, R.N., Haverkamp, W., Jongsma, H.J., Kleber, A.G., McKenna, W.J., Roden, D.M., Rudy, Y., Schwartz, K., Schwartz, P.J., Towbin, J.A. and Wilde, A.M. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management part III. Circulation, 1999, 99, 674-681.
5. Wang, Q., Curran, M. E., Splawski, I., Burn, T. C., Millholland, J. M., VanRaay, T. J., Shen, J., Timothy, K. W., Vincent, G. M., de Jager, T., Schwartz, P. J., Toubin, J. A., Moss, A. J., Atkinson, D. L., Landes, G. M., Connors, T. D. and Keating, M. T. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat. Genet., 1996, 12(1), 17-23.
6. Curran, M. E., Splawski, I., Timothy, K. W., Vincent, G. M., Green, E. D. and Keating, M. T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell, 1995, 80(5), 795-803.
7. Wang, Q., Shen, J., Li, Z., Timothy, K., Vincent, G.M., Priori, S.G., Schwartz, P.J. and Keating, M.T. Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum. Mol. Genet., 1995, 4, 1603-1607.
8. Barhanin, J., Lesage, F., Guillemare, E., Fink, M., Lazdunski, M. and Romey, G. K. (V)LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current. Nature, 1996, 384(6604), 78-80.
9. Sanguinetti, M. C., Curran, M. E., Zou, A., Shen, J., Spector, P. S., Atkinson, D. L. and Keating, M. T. Coassembly of K(V)LQT1 and minK (lsK) proteins to form cardiac I(Ks) potassium channel. Nature, 1996, 384(6604), 80-83.
10. Abbott, G. W., Sesti, F., Splawski, I., Buck, M. E., Lehmann, M. H., Timothy, K. W., Keating, M. T. and Goldstein, S. A. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell, 1999, 97(2), 175-187.
11. Splawski, I., Shen, J., Timothy, K. W., Lehmann, M. H., Priori, S., Robinson, J. L., Moss, A. J., Schwartz, P. J., Towbin, J. A., Vincent, G. M. and Keating, M. T. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation, 2000, 102(10), 1178-1185.
12. Zhou, Z., Gong, Q., Epstein, M.L. and January C.T. HERG channel dysfunction in human long QT syndrome. Intracellular transport and functional defects. J. Biol. Chem., 1998, 273, 21061-21066.
13. Priori, S. G. and Long, Q.T. Brugada syndromes: from genetics to clinical management. J. Cardiovasc. Electrophysiol., 2000, 11(10), 1174-1178.
14. Wang, Q., Shen, J., Splawski, I., Atkinson, D., Li, Z., Robinson, J. L., Moss, A. J., Towbin, J. A. and Keating, M. T. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell, 1995, 80(5), 805-811.
15. Zehender, M., Hohnloser, S. and Just, H. QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards. Cardiovasc. Drugs Ther., 1991, 5, 515-530.
16. Napolitano, C., Schwartz, P.J., Brown, A.M., Ronchetti, E., Bianchi, L., Pinnavaia, A., Acquaro, G. and Priori, S.G. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J. Cardiovasc. Electrophysiol., 2000, 11, 691-696.
17. Sesti, F., Abbott, G.W., Wei, J., Murray, K.T., Saksena, S., Schwartz, P.J., Priori, S.G., Roden, D.M., George, A.L. Jr, and Goldstein, S.A. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc. Natl. Acad. Sci. USA, 2000, 97, 10613-10618.
18. Wei, J., Wang, D. W., Alings, M., Fish, F., Wathen, M., Roden, D. M. and George, A. L. Jr. Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na+ channel. Circulation, 1999, 99(24), 3165-3171.
19. Roden, D.M. Mechanisms and management of proarrhythmia. Am. J. Cardiol., 1998, 82, 491-571.
20. Roden, D.M., Woosley, R.L. and Primm, R.K. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am. Heart. J., 1986, 111, 1088-1093.
21. Balser, J.R., Bennett, P.B., Hondeghem, L.M. and Roden, D.M. Suppression of time-dependent outward current in guinea pig ventricular myocytes. Actions of quinidine and amiodarone. Circ. Res., 1991, 69, 519-529.
22. Haverkamp, W., Breithardt, G., Camm, A.J., Janse, M.J., Rosen, M.R., Antzelevitch, C., Escande, D., Franz, M., Malik, M., Moss, A. and Shah, R. The potential for QT prolongation and proarrhythmia by non- antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur. Heart. J., 2000, 21, 1216-1231.
23. Maisel, W.H., Kuntz, K.M., Reimold, S.C., Lee, T.H., Antman, E.M., Friedman, P.L. and Stevenson, W.G. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann. Intern. Med., 1997, 127, 281-284.
24. Reiffel, J.A. Inpatient versus outpatient antiarrhythmic drug initiation: safety and cost-effectiveness issues. Curr. Opin. Cardiol., 2000, 15, 7-11.
25. Chevalier, P., Rodriguez, C., Bontemps, L., Miquel M., Kirkorian, G., Rousson, R., Potet, F., Schott, J.J., Baro, I. and Touboul, P. Non-invasive testing of acquired long QT syndrome: evidence for multiple arrhythmogenic substrates. Cardiovasc. Res., 2001, 50, 386-398.
26. Kay, G.N., Plumb, V.J., Arciniegas, J.G., Henthorn, R.W. and Waldo, A.L. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J. Am. Coll. Cardiol., 1983, 2, 806-817.
27. Houltz, B., Darpo, B., Edvardsson, N., Blomstrom, P., Brachmann, J., Crijns, H.J., Jensen, S.M., Svernhage, E., Vallin, H. and Swedberg, K. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. Pacing. Clin. Electrophysiol., 1998, 21, 1044-1057.
28. Waldo, A.L., Camm, A.J., deRuyter, H., Friedman, P.L., MacNeil, D.J., Pauls, J.F., Pitt, B., Pratt C.M., Schwartz, P.J. and Veltri, E.P. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet, 1996, 348, 7-12.
29. Vos, M.A., de Groot, S.H., Verduyn, S.C., van der Zande, J., Leunissen, H.D., Cleutjens, J.P., van Bilsen, M., Daemen, M.J., Schreuder, J.J., Allessie, M. A. and Wellens, H.J. Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. Circulation, 1998, 98, 1125-1135.
30. Nabauer, M. and Kaab, S. Potassium channel down-regulation in heart failure. Cardiovasc. Res., 1998, 37, 324-334.
31. Torp-Pedersen, C., Moller, M., Bloch-Thomsen, P.E., Kober, L., Sandoe, E., Egstrup, K., Agner, E., Carlsen, J., Videbaek, J., Marchant, B. and Camm ,A.J. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N. Engl. J. Med., 1999, 341, 857-865.
32. Hohnloser, S.H. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. Am. J. Cardiol., 1997, 80, 82G-89G.
33. Howard, P.A. Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter. Ann. Pharmacother, 1999, 33, 38-47.
34. Stambler, B.S., Wood, M.A., Ellenbogen, K.A., Perry, K.T., Wakefield, L.K. and VanderLugt, J.T. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation, 1996, 94, 1613-1621.
35. Hohnloser, S.H., Klingenheben, T. and Singh, B.N. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann. Intern. Med., 1994, 121, 529-535.
36. Takanaka, C. and Singh, B.N. Barium-induced nondriven action potentials as a model of triggered potentials from early afterdepolarizations: significance of slow channel activity and differing effects of quinidine and amiodarone. J. Am. Coll. Cardiol., 1990, 15, 213-221.
37. Mitcheson, J.S., Chen, J., Lin, M., Culberson, C. and Sanguinetti, M.C. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. USA, 2000, 97, 12329-12333.
38. Shimizu, W., Kamakura, S., Kurita, T., Suyama, K., Aihara, N. and Shimomura, K. Influence of epinephrine, propranolol, and atrial pacing on spatial distribution of recovery time measured by body surface mapping in congenital long QT syndrome. J. Cardiovasc. Electrophysiol., 1997, 8, 1102-1114.
39. Shimizu, W. and Antzelevitch, C. Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation, 1998, 98(21), 2314-2322.
40. Jurkiewicz, N.K. and Sanguinetti, M.C. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circ. Res., 1993, 72, 75-83.
41. Hondeghem, L.M., Carlsson, L. and Duker, G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation, 2001, 103, 2004-2013.
42. El-Sherif, N., Caref, E.B., Yin, H. and Restivo, M. The electrophysiological mechanism of ventricular arrhythmias in the Long QT syndrome. Tridimensional mapping of activation and recovery patterns. Circulation Research, 1996, 79, 474-492.
43. Antzelevitch, C., Sun, Z.Q., Zhang, Z.Q. and Yan, G.X. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J. Am. Coll. Cardiol., 1996, 28, 1836-1848.
44. Jackman, W.M., Friday, K.J., Anderson, J.L., Aliot, E.M., Clark, M. and Lazzara, R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog. Cardiovasc. Dis., 1988, 31, 115-172.
45. Melichercik, J., Brachmann, J., Schols, W., Hilbel, T., Beyer, T. and Kubler, W. Rate and time dependent effects of D-sotalol on the monophasic action potential after sudden increase of the heart rate. Pacing. Clin. Electrophysiol., 1999, 22, 65-72.
46. Tzivoni, D., Banai, S., Schuger, C., Benhorin, J., Keren, A., Gottlieb, S. and Stern, S. Treatment of torsade de pointes with magnesium sulfate. Circulation, 1988, 77, 392-397.
47. Duff, H.J., Feng, Z.P., Fiset, C., Wang, L., Lees-Miller, J. and Sheldon, R.S. [3H]dofetilide binding to cardiac myocytes: modulation by extracellular potassium. J. Mol. Cell. Cardiol., 1997, 29, 183-191.
48. Yang, T. and Roden, D.M. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation, 1996, 93, 407-411.
49. Choy, A.M., Lang, C.C., Chomsky, D.M., Rayos, G.H,, Wilson, J.R. and Roden, D.M. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation, 1997, 96, 2149-2154.